MCID: ESS001
MIFTS: 57

Essential Tremor

Categories: Rare diseases, Neuronal diseases, Genetic diseases

Aliases & Classifications for Essential Tremor

MalaCards integrated aliases for Essential Tremor:

Name: Essential Tremor 12 53 25 54 37 29 55 6 44 15 73
Hereditary Essential Tremor 53 25 6
Benign Essential Tremor 12 53 25
Essential Tremor, Susceptibility to 13 6
Familial Tremor 25 73
Benign Essential Tremor Syndrome 76
Tremor, Hereditary Essential, 1 53
Essential Hereditary Tremor 12
Tremor Hereditary Essential 76
Familial Essential Tremor 53
Presenile Tremor Syndrome 53
Shaky Hand Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4990
ICD10 33 G25.0
MeSH 44 D020329
KEGG 37 H01577

Summaries for Essential Tremor

NINDS : 54 Tremor is an unintentional, somewhat rhythmic, muscle movement involving to-and-fro movements (oscillations) of one or more parts of the body. Essential tremor (previously called benign essential tremor) is the most common form of abnormal tremor. (In some people, tremor is a symptom of a neurological disorder or appears as a side effect of certain drugs.)  Although it may be mild and nonprogressive in some people, in others the tremor is slowly progressive, starting on one side of the body but eventually affecting both sides. Hand tremor is most common but the head, arms, voice, tongue, legs, and trunk may also be involved. Hand tremor may cause problems with purposeful movements such as eating, writing, sewing, or shaving. Head tremor may be seen as a "yes-yes" or "no-no" motion. Essential tremor may be accompanied by mild gait disturbance. Heightened emotion, stress, fever, physical exhaustion, or low blood sugar may trigger tremors or increase their severity. There may be mild degeneration in the certain parts of the cerebellum in persons with essential tremor.  Onset is most common after age 40, although symptoms can appear at any age. Children of a parent who has essential tremor have up to a 50 percent chance of inheriting the condition. Essential tremor is not associated with any known pathology.

MalaCards based summary : Essential Tremor, also known as hereditary essential tremor, is related to rem sleep behavior disorder and tremor, and has symptoms including essential and other specified forms of tremor, tremor and senile tremor. An important gene associated with Essential Tremor is ETM2 (Essential Tremor 2), and among its related pathways/superpathways are Neuroscience and Parkinsons Disease Pathway. The drugs Dopamine and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include brain, cerebellum and tongue, and related phenotype is nervous system.

Disease Ontology : 12 A movement disorder that causes involuntary tremors, especially in the hands. It occurs alone without other neurological signs and symptoms.

Genetics Home Reference : 25 Essential tremor is a movement disorder that causes involuntary, rhythmic shaking (tremor), especially in the hands. It is distinguished from tremor that results from other disorders or known causes, such as Parkinson disease or head trauma. Essential tremor usually occurs alone, without other neurological signs or symptoms. However, some experts think that essential tremor can include additional features, such as mild balance problems.

NIH Rare Diseases : 53 Essential tremor is the most common movement disorder.  It is characterized by involuntary and rhythmic shaking (tremor), especially in the hands, without any other signs or symptoms. It is distinguished from tremor that results from other disorders or known causes, such as tremors seen with Parkinson disease or head trauma. Most cases of essential tremor are hereditary. There are five forms of essential tremor that are based on different genetic causes. Several genes as well as lifestyle and environmental factors likely play a role in a person's risk of developing this complex condition. In mild cases, treatment may not be necessary. In cases where symptoms interfere with daily living, medications may help to relieve symptoms.     

Wikipedia : 76 Essential tremor (ET, also referred to as benign tremor, familial tremor, or idiopathic tremor) is a... more...

Related Diseases for Essential Tremor

Diseases in the Tremor family:

Tremor, Hereditary Essential, 1 Tremor, Hereditary Essential, 2
Tremor, Hereditary Essential, 3 Tremor, Hereditary Essential, 4
Tremor, Hereditary Essential, 5 Essential Tremor

Diseases related to Essential Tremor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Related Disease Score Top Affiliating Genes
1 rem sleep behavior disorder 29.7 LRRK2 SLC6A3 SNCA
2 tremor 29.7 DNAJC13 DRD3 FMR1 FUS HTRA2 LRRK2
3 multiple system atrophy 1 29.6 LRRK2 PRKN SLC6A3 SNCA
4 restless legs syndrome 29.5 DRD3 PRKN SLC6A3 SNCA
5 supranuclear palsy, progressive, 1 29.3 LRRK2 PRKN SLC6A3 SNCA
6 dementia 29.0 FUS LRRK2 PRKN SLC6A3 SNCA
7 movement disease 28.6 DRD3 FMR1 LRRK2 PRKN SLC6A3 SNCA
8 parkinson disease, late-onset 27.8 CHCHD2 DNAJC13 DRD3 LRRK2 PRKN SLC6A3
9 sensorineural hearing loss-early graying-essential tremor syndrome 12.1
10 tremor, hereditary essential, 1 11.8
11 tremor, hereditary essential, 5 11.6
12 tremor, nystagmus, and duodenal ulcer 11.1
13 tremor, hereditary essential, 2 11.1
14 tremor, hereditary essential, 3 11.1
15 tremor, hereditary essential, 4 11.1
16 mental retardation, autosomal recessive 48 11.1
17 nephronophthisis-like nephropathy 1 10.9
18 x-linked dystonia-parkinsonism/lubag 10.9
19 dystonia 10.3
20 postencephalitic parkinson disease 10.3 LRRK2 SNCA
21 hereditary late-onset parkinson disease 10.3 DNAJC13 LRRK2 SNCA
22 aging 10.3
23 leukoencephalopathy, hereditary diffuse, with spheroids 10.3 SLC1A2 SNCA
24 bell's palsy 10.2 HS1BP3 PRKN
25 cervical dystonia 10.1
26 cervicitis 10.1
27 depression 10.1
28 parkinson disease 10 10.1 LRRK2 PRKN SNCA
29 alzheimer disease 10.0
30 parkinson disease 3, autosomal dominant 10.0 LRRK2 PRKN SNCA
31 toxic encephalopathy 10.0 SLC1A2 SLC6A3 SNCA
32 striatonigral degeneration 10.0 SLC6A3 SNCA
33 neuronitis 10.0
34 pathological gambling 10.0 DRD3 SLC6A3
35 early-onset parkinson's disease 9.9 LRRK2 PRKN SNCA
36 motor neuron disease 9.9 FUS SLC1A2 SNCA
37 torticollis 9.8
38 sarcoma 9.8
39 autosomal dominant cerebellar ataxia 9.8
40 cerebritis 9.8
41 classic progressive supranuclear palsy syndrome 9.8
42 amyotrophic lateral sclerosis 1 9.7
43 obsessive-compulsive disorder 9.7
44 spinocerebellar ataxia 1 9.7
45 hydrocephalus, normal-pressure 9.7
46 apraxia of eyelid opening 9.7
47 aceruloplasminemia 9.7
48 body mass index quantitative trait locus 1 9.7
49 ataxia-oculomotor apraxia 3 9.7
50 hereditary ataxia 9.7

Graphical network of the top 20 diseases related to Essential Tremor:



Diseases related to Essential Tremor

Symptoms & Phenotypes for Essential Tremor

UMLS symptoms related to Essential Tremor:


essential and other specified forms of tremor, tremor, senile tremor, action tremor, physiological tremor

MGI Mouse Phenotypes related to Essential Tremor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.32 FMR1 HTRA2 LINGO1 LRRK2 PRKN SLC1A2

Drugs & Therapeutics for Essential Tremor

Drugs for Essential Tremor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
2
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
3
Memantine Approved, Investigational Phase 4 19982-08-2 4054
4
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
5
Propranolol Approved, Investigational Phase 4,Not Applicable 525-66-6 4946
6
Iodine Approved, Investigational Phase 4 7553-56-2 807
7 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
8 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Dopamine Agents Phase 4,Phase 3
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Botulinum Toxins Phase 4,Phase 3,Phase 2,Not Applicable
13 Analgesics Phase 4,Phase 2,Phase 3,Not Applicable
14 calcium channel blockers Phase 4,Phase 2
15 Adrenergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
16 Adrenergic Antagonists Phase 4,Not Applicable
17 Adrenergic beta-Antagonists Phase 4,Not Applicable
18 Tranquilizing Agents Phase 4
19 Anti-Anxiety Agents Phase 4
20 Anti-Arrhythmia Agents Phase 4,Not Applicable
21 Vasodilator Agents Phase 4,Not Applicable
22 Pharmaceutical Solutions Phase 4,Phase 2
23 Antihypertensive Agents Phase 4,Not Applicable
24 Excitatory Amino Acid Antagonists Phase 4
25 Excitatory Amino Acids Phase 4
26 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Antiparkinson Agents Phase 4,Phase 3
28 Psychotropic Drugs Phase 4
29 Calcium, Dietary Phase 4,Phase 2
30 cadexomer iodine Phase 4
31 Calamus Nutraceutical Phase 4
32
Cocaine Approved, Illicit Phase 3 50-36-2 5760 446220
33
Topiramate Approved Phase 3 97240-79-4 5284627
34
Dexmedetomidine Approved, Vet_approved Phase 2, Phase 3,Not Applicable 113775-47-6 68602 5311068
35 abobotulinumtoxinA Phase 3,Phase 2,Not Applicable
36 Neurotransmitter Uptake Inhibitors Phase 3
37 Anesthetics Phase 3,Phase 2,Not Applicable
38 Anesthetics, Local Phase 3,Not Applicable
39 onabotulinumtoxinA Phase 3,Phase 2,Not Applicable
40 Vasoconstrictor Agents Phase 3
41 Dopamine Uptake Inhibitors Phase 3
42 Botulinum Toxins, Type A Phase 3,Phase 2,Not Applicable
43 Neuroprotective Agents Phase 3,Phase 1,Phase 2
44 Anti-Obesity Agents Phase 3
45 Antioxidants Phase 3,Phase 2,Not Applicable
46 Protective Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Adrenergic Agonists Phase 2, Phase 3,Not Applicable
48 Adrenergic alpha-2 Receptor Agonists Phase 2, Phase 3,Not Applicable
49 Adrenergic alpha-Agonists Phase 2, Phase 3,Not Applicable
50 Analgesics, Non-Narcotic Phase 2, Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 141)
# Name Status NCT ID Phase Drugs
1 Pregabalin in the Treatment of Essential Tremor Completed NCT00646451 Phase 4 pregabalin;placebo capsules
2 A Pilot Clinical Trial Of Memantine for Essential Tremor Completed NCT00439699 Phase 4 Memantine
3 Pregabalin (Lyrica) for the Treatment of Essential Tremor Completed NCT00584376 Phase 4 Pregabalin;Placebo
4 Propranolol and Botulinum Toxin for Essential Vocal Tremor Completed NCT02111369 Phase 4 Propranolol
5 RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR) Completed NCT00998660 Phase 4
6 A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms Completed NCT00382967 Phase 4
7 Atlas Predicted DBS Settings in Essential Tremor Enrolling by invitation NCT02678429 Phase 4
8 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
9 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor Unknown status NCT02555982 Phase 3 BOTOX ® 200 Unités;Placebo
10 Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor Unknown status NCT00724906 Phase 3 123 I - ALTROPANE®
11 Novel Therapies for Essential Tremor Completed NCT00018564 Phase 3 treatments for essential tremor
12 A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause. Completed NCT00236496 Phase 3 topiramate
13 Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients Completed NCT00468078 Phase 3 F-18 FPCIT
14 Pre-lemniscal Radiation Deep Brain Stimulation for ET Terminated NCT00634478 Phase 2, Phase 3
15 Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor Withdrawn NCT01441284 Phase 3 pramipexole;placebo
16 Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation Withdrawn NCT00608231 Phase 2, Phase 3 Dexmedetomidine Hydrochloride Infusion;Normal Saline
17 Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor Unknown status NCT01945567 Phase 2
18 Deep Brain Frameless Radiosurgery for Drug Resistant Invalidating Tremor. Dose Escalation Pilot Study Unknown status NCT02585583 Phase 2
19 A Pilot Efficacy and Safety Study of ST101 in Essential Tremor Completed NCT01332695 Phase 2 ST101;Placebo
20 A Study to Evaluate SAGE-217 in Subjects With Essential Tremor Completed NCT02978781 Phase 2 SAGE-217;Placebo
21 A Safety/Efficacy Trial of Zonisamide for Essential Tremor Completed NCT00223743 Phase 2 Zonisamide
22 Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor Completed NCT00598078 Phase 2 Sodium Oxybate;Sodium Oxybate
23 Evaluate SAGE-547 in Patients With Essential Tremor Completed NCT02277106 Phase 2 SAGE-547;Placebo
24 A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor Completed NCT00524056 Phase 2 Carisbamate;Placebo
25 Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor Completed NCT00848172 Phase 1, Phase 2 Octanoic Acid;Placebo
26 Efficacy of Levetiracetam in Essential Tremor Completed NCT00620165 Phase 1, Phase 2 levetiracetam;placebo
27 Octanol to Treat Essential Tremor Completed NCT00080366 Phase 2 1-Octanol
28 Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor Completed NCT00102596 Phase 2 1-Octanol
29 Botulinum Toxin A to Treat Arm Tremor Completed NCT02207946 Phase 2 IncobotulinumtoxinA;Placebo
30 Effects of Octanoic Acid for Treatment of Essential Voice Tremor Completed NCT01864525 Phase 1, Phase 2 Octanoic acid;Placebo pill
31 Botulinum Toxin Type A for Injection of Bilateral Upper Extremity Tremor in Patients With Essential Tremor Using Kinematic Assessment Recruiting NCT02551848 Phase 2 Botulinum toxin type A (Xeomin®)
32 A Phase 2 RCT Study of CX-8998 for Essential Tremor Recruiting NCT03101241 Phase 2 CX-8998;Placebo
33 Deep Brain Stimulation for Voice Tremor: Left, Right, or Both Hemispheres? Recruiting NCT02960243 Phase 1, Phase 2
34 Kinematic Characterization of Upper Limb Parkinson's Disease Tremor for Optimized Botulinum Toxin Type A Therapy Recruiting NCT02668497 Phase 2 Botulinum Toxin Type A
35 An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor Active, not recruiting NCT02668146 Phase 2 Perampanel;Placebo
36 Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease Active, not recruiting NCT02427646 Phase 2 IncobotulinumtoxinA
37 T2000 in Essential Tremor - Open Label Continuation Terminated NCT00655278 Phase 2 T2000
38 A Study of T2000 in Essential Tremor Terminated NCT00321087 Phase 2 T2000;T2000;T2000
39 Octanoic Acid for Essential Tremor Completed NCT01468948 Phase 1 Octanoic Acid
40 ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor Completed NCT02037217 Phase 1
41 ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor Completed NCT01304758 Phase 1
42 1-Octanol to Treat Essential Tremor Completed NCT00016679 Phase 1 1-Octanol
43 1-Octanol to Treat Essential Tremor Completed NCT00001986 Phase 1 1-Octanol
44 Magnetic Resonance (MR) Guided Functional Ultrasound-Neurosurgery for Movement Disorders Completed NCT01698450 Phase 1
45 Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial Recruiting NCT02558634 Phase 1
46 Imaging in the Diagnosis of Parkinson's Disease and Essential Tremor Unknown status NCT01446939
47 Evaluation of Bilateral Gamma Knife Thalamotomy in Patients Presenting With Severe Essential Tremor Unknown status NCT02827955 Not Applicable
48 Deep Brain Stimulation (DBS) for the Suppression of Tremor Unknown status NCT02087046 Not Applicable
49 Validation of DaTscan for Detection of Parkinson Disease Related Disorders Unknown status NCT02138682 l-123 Ioflupane
50 Decision-making and Emotion Recognition in Essential Tremor Completed NCT01223144 Not Applicable

Search NIH Clinical Center for Essential Tremor

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: essential tremor

Genetic Tests for Essential Tremor

Genetic tests related to Essential Tremor:

# Genetic test Affiliating Genes
1 Essential Tremor 29

Anatomical Context for Essential Tremor

MalaCards organs/tissues related to Essential Tremor:

41
Brain, Cerebellum, Tongue, Thalamus, Cortex, Testes, Eye

Publications for Essential Tremor

Articles related to Essential Tremor:

(show top 50) (show all 777)
# Title Authors Year
1
Caffeine Consumption in First-Degree Relatives of Essential Tremor Cases: Evidence of Dietary Modification Before Disease Onset. ( 29953981 )
2018
2
Deep Brain Stimulation Management of Essential Tremor with Dystonic Features. ( 29971197 )
2018
3
Objective predictors of 'early tolerance' to ventral intermediate nucleus of thalamus deep brain stimulation in essential tremor patients. ( 29908405 )
2018
4
Unilateral Left Deep Brain Stimulation of the Caudal Zona Incerta Is Equally Effective on Voice Tremor as Bilateral Stimulation: Evidence from 7 Patients with Essential Tremor. ( 29975951 )
2018
5
The effects of Thalamic Deep Brain Stimulation on speech dynamics in patients with Essential Tremor: An articulographic study. ( 29360867 )
2018
6
Magnetic resonance-guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson's disease and essential tremor cases. ( 28298022 )
2018
7
White matter measures correlate with essential tremor severity-A pilot diffusion tensor imaging study. ( 29964316 )
2018
8
Clinical response to Vim's thalamic stereotactic radiosurgery for essential tremor is associated with distinctive functional connectivity patterns. ( 29335882 )
2018
9
Comparative Burden of Subclinical Tremor in a Cohort of Normal Individuals Stratified by Familial Risk for Essential Tremor. ( 29339654 )
2018
10
A method for pre-operative single-subject thalamic segmentation based on probabilistic tractography for essential tremor deep brain stimulation. ( 29307012 )
2018
11
Essential tremor: "Plus" or "Minus". Perhaps now is the time to adopt the term "the essential tremors". ( 29937098 )
2018
12
Hand Tremor Questionnaire: A Useful Screening Tool for Differentiating Patients with Hand Tremor between Parkinson's Disease and Essential Tremor. ( 29971978 )
2018
13
Dysgeusia in deep brain stimulation for essential tremor. ( 29402567 )
2018
14
Pretherapeutic motor thalamus resting-state functional connectivity with visual areas predicts tremor arrest after thalamotomy for essential tremor: tracing the cerebello-thalamo-visuo-motor network. ( 29920392 )
2018
15
Clinical, electrophysiological, and imaging study in essential tremor-Parkinson's disease syndrome. ( 29885986 )
2018
16
Letter to the Editor. Magnetic resonance-guided focused ultrasound and essential tremor. ( 29961391 )
2018
17
Long Trace Eyeblink Conditioning Is Largely Preserved in Essential Tremor. ( 29916048 )
2018
18
Serum concentration and clinical significance of brain-derived neurotrophic factor in patients with Parkinson's disease or essential tremor. ( 29350074 )
2018
19
Shaky and unsteady: Dynamic posturography in essential tremor. ( 29406890 )
2018
20
Effects on cognition and quality of life with unilateral magnetic resonance-guided focused ultrasound thalamotomy for essential tremor. ( 29385928 )
2018
21
Thalamic Deep Brain Stimulation Salvages Failed Focused Ultrasound Thalamotomy for Essential Tremor: A Case Report. ( 29433124 )
2018
22
A Novel Posture for Better Differentiation Between Parkinson's Tremor and Essential Tremor. ( 29867328 )
2018
23
Association study of essential tremor genetic loci in Parkinson'sA disease. ( 29398123 )
2018
24
Inferior Olivary nucleus degeneration does not lessen tremor in essential tremor. ( 29372062 )
2018
25
Essential tremor. ( 29325613 )
2018
26
DBS of the PSA and the VIM in essential tremor: A randomized, double-blind, crossover trial. ( 29970404 )
2018
27
A meta-analysis of outcomes and complications of magnetic resonance-guided focused ultrasound in the treatment of essential tremor. ( 29385917 )
2018
28
Conditions Associated with Essential Tremor in Veterans: A Potential Role for Chronic Stress. ( 29971194 )
2018
29
Validating the targets for neurostimulation in essential tremor. ( 29970402 )
2018
30
Pretherapeutic Functional Imaging Allows Prediction of Head Tremor Arrest After Thalamotomy for Essential Tremor: The Role of Altered Interconnectivity Between Thalamolimbic and Supplementary Motor Circuits. ( 29410136 )
2018
31
Knowledge about Essential Tremor: A Study of Essential Tremor Families. ( 29434571 )
2018
32
Corrigendum: Digitizing Tablet and Fahn-Tolosa-MarA-n Ratings of Archimedes Spirals have Comparable Minimum Detectable Change in Essential Tremor. ( 29971202 )
2018
33
Uric acid level may not be reduced in essential tremor. ( 29936882 )
2018
34
Essential tremor and the cerebellum. ( 29891062 )
2018
35
Double target DBS for essential tremor: 8-contact lead for cZI and vim aligned in the same trajectory. ( 29438045 )
2018
36
Preliminary experience with a transcranial magnetic resonance-guided focused ultrasound surgery system integrated with a 1.5-T MRI unit in a series of patients with essential tremor and Parkinson's disease. ( 29385927 )
2018
37
A method for characterizing essential tremor from the shoulder to the wrist. ( 29428341 )
2018
38
Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor. ( 29958776 )
2018
39
Focused Ultrasound for Essential Tremor: Review of the Evidence and Discussion of Current Hurdles. ( 28503363 )
2017
40
Delta-amino-levulinic acid dehydratase gene and essential tremor. ( 28276576 )
2017
41
The Experience of Essential Tremor Caregivers: Burden and Its Correlates. ( 28855888 )
2017
42
Thalamic DBS with a constant-current device in essential tremor: AA controlled clinical trial. ( 28400200 )
2017
43
Nonmotor Symptoms in Essential Tremor and Other Tremor Disorders. ( 28805576 )
2017
44
Brain positron emission tomography with 2-(18)F-2-deoxi-D-glucose of patients with dystonia and essential tremor detects differences between these disorders. ( 28805131 )
2017
45
Role of altered cerebello-thalamo-cortical network in the neurobiology of essential tremor. ( 28062908 )
2017
46
Clinical Characteristics of Parkinson's Disease Developed from Essential Tremor. ( 28409750 )
2017
47
Action Tremor Asymmetry Profile Does Not Aggregate in Families with Essential Tremor. ( 28469594 )
2017
48
A Network Model of Local Field Potential Activity in Essential Tremor and the Impact of Deep Brain Stimulation. ( 28068428 )
2017
49
Neural computational modeling reveals a major role of corticospinal gating of central oscillations in the generation of essential tremor. ( 29323043 )
2017
50
Emotion modulation of the startle reflex in essential tremor: Blunted reactivity to unpleasant and pleasant pictures. ( 27887893 )
2017

Variations for Essential Tremor

ClinVar genetic disease variations for Essential Tremor:

6
(show all 40)
# Gene Variation Type Significance SNP ID Assembly Location
1 DRD3 NM_000796.5(DRD3): c.691T> A (p.Cys231Ser) single nucleotide variant Uncertain significance rs150042478 GRCh38 Chromosome 3, 114139532: 114139532
2 DRD3 NM_000796.5(DRD3): c.691T> A (p.Cys231Ser) single nucleotide variant Uncertain significance rs150042478 GRCh37 Chromosome 3, 113858379: 113858379
3 DRD3 NM_000796.5(DRD3): c.302T> G (p.Ile101Ser) single nucleotide variant Uncertain significance rs886057789 GRCh38 Chromosome 3, 114159836: 114159836
4 DRD3 NM_000796.5(DRD3): c.302T> G (p.Ile101Ser) single nucleotide variant Uncertain significance rs886057789 GRCh37 Chromosome 3, 113878683: 113878683
5 DRD3 NM_000796.5(DRD3): c.821G> A (p.Gly274Glu) single nucleotide variant Uncertain significance rs200825904 GRCh38 Chromosome 3, 114131303: 114131303
6 DRD3 NM_000796.5(DRD3): c.821G> A (p.Gly274Glu) single nucleotide variant Uncertain significance rs200825904 GRCh37 Chromosome 3, 113850150: 113850150
7 DRD3 NM_000796.5(DRD3): c.-105G> A single nucleotide variant Likely benign rs36211802 GRCh38 Chromosome 3, 114178726: 114178726
8 DRD3 NM_000796.5(DRD3): c.-105G> A single nucleotide variant Likely benign rs36211802 GRCh37 Chromosome 3, 113897573: 113897573
9 DRD3 NM_000796.5(DRD3): c.-252C> T single nucleotide variant Likely benign rs36211803 GRCh38 Chromosome 3, 114178873: 114178873
10 DRD3 NM_000796.5(DRD3): c.-252C> T single nucleotide variant Likely benign rs36211803 GRCh37 Chromosome 3, 113897720: 113897720
11 DRD3 NM_000796.5(DRD3): c.-281A> G single nucleotide variant Uncertain significance rs199852439 GRCh38 Chromosome 3, 114178902: 114178902
12 DRD3 NM_000796.5(DRD3): c.-281A> G single nucleotide variant Uncertain significance rs199852439 GRCh37 Chromosome 3, 113897749: 113897749
13 DRD3 NM_000796.5(DRD3): c.-286A> C single nucleotide variant Likely benign rs190248679 GRCh38 Chromosome 3, 114178907: 114178907
14 DRD3 NM_000796.5(DRD3): c.-286A> C single nucleotide variant Likely benign rs190248679 GRCh37 Chromosome 3, 113897754: 113897754
15 DRD3 NM_000796.5(DRD3): c.270+14A> G single nucleotide variant Uncertain significance rs75091114 GRCh38 Chromosome 3, 114171709: 114171709
16 DRD3 NM_000796.5(DRD3): c.270+14A> G single nucleotide variant Uncertain significance rs75091114 GRCh37 Chromosome 3, 113890556: 113890556
17 DRD3 NM_000796.5(DRD3): c.-114A> G single nucleotide variant Uncertain significance rs886057790 GRCh38 Chromosome 3, 114178735: 114178735
18 DRD3 NM_000796.5(DRD3): c.-114A> G single nucleotide variant Uncertain significance rs886057790 GRCh37 Chromosome 3, 113897582: 113897582
19 DRD3 NM_000796.5(DRD3): c.-153T> G single nucleotide variant Uncertain significance rs200345655 GRCh38 Chromosome 3, 114178774: 114178774
20 DRD3 NM_000796.5(DRD3): c.-153T> G single nucleotide variant Uncertain significance rs200345655 GRCh37 Chromosome 3, 113897621: 113897621
21 DRD3 NM_000796.5(DRD3): c.-318C> T single nucleotide variant Uncertain significance rs201561838 GRCh38 Chromosome 3, 114178939: 114178939
22 DRD3 NM_000796.5(DRD3): c.-318C> T single nucleotide variant Uncertain significance rs201561838 GRCh37 Chromosome 3, 113897786: 113897786
23 DRD3 NM_000796.5(DRD3): c.1151C> A (p.Thr384Asn) single nucleotide variant Uncertain significance rs886057788 GRCh38 Chromosome 3, 114128768: 114128768
24 DRD3 NM_000796.5(DRD3): c.1151C> A (p.Thr384Asn) single nucleotide variant Uncertain significance rs886057788 GRCh37 Chromosome 3, 113847615: 113847615
25 DRD3 NM_000796.5(DRD3): c.1077C> T (p.His359=) single nucleotide variant Uncertain significance rs3732791 GRCh38 Chromosome 3, 114128842: 114128842
26 DRD3 NM_000796.5(DRD3): c.1077C> T (p.His359=) single nucleotide variant Uncertain significance rs3732791 GRCh37 Chromosome 3, 113847689: 113847689
27 DRD3 NM_000796.5(DRD3): c.987A> G (p.Gln329=) single nucleotide variant Likely benign rs61735073 GRCh38 Chromosome 3, 114131137: 114131137
28 DRD3 NM_000796.5(DRD3): c.987A> G (p.Gln329=) single nucleotide variant Likely benign rs61735073 GRCh37 Chromosome 3, 113849984: 113849984
29 DRD3 NM_000796.5(DRD3): c.720A= (p.Gln240=) single nucleotide variant Likely benign rs2251177 GRCh38 Chromosome 3, 114139503: 114139503
30 DRD3 NM_000796.5(DRD3): c.720A= (p.Gln240=) single nucleotide variant Likely benign rs2251177 GRCh37 Chromosome 3, 113858350: 113858350
31 DRD3 NM_000796.5(DRD3): c.383+7C> T single nucleotide variant Uncertain significance rs200206712 GRCh38 Chromosome 3, 114159748: 114159748
32 DRD3 NM_000796.5(DRD3): c.383+7C> T single nucleotide variant Uncertain significance rs200206712 GRCh37 Chromosome 3, 113878595: 113878595
33 DRD3 NM_000796.5(DRD3): c.51A> G (p.Ala17=) single nucleotide variant Likely benign rs3732783 GRCh38 Chromosome 3, 114171942: 114171942
34 DRD3 NM_000796.5(DRD3): c.51A> G (p.Ala17=) single nucleotide variant Likely benign rs3732783 GRCh37 Chromosome 3, 113890789: 113890789
35 DRD3 NM_000796.5(DRD3): c.-38A> C single nucleotide variant Uncertain significance rs201872343 GRCh38 Chromosome 3, 114178659: 114178659
36 DRD3 NM_000796.5(DRD3): c.-38A> C single nucleotide variant Uncertain significance rs201872343 GRCh37 Chromosome 3, 113897506: 113897506
37 DRD3 NM_000796.5(DRD3): c.-333G> A single nucleotide variant Likely benign rs36212175 GRCh37 Chromosome 3, 113897801: 113897801
38 DRD3 NM_000796.5(DRD3): c.-333G> A single nucleotide variant Likely benign rs36212175 GRCh38 Chromosome 3, 114178954: 114178954
39 DRD3 NM_000796.5(DRD3): c.-388T> A single nucleotide variant Uncertain significance rs886057791 GRCh38 Chromosome 3, 114179009: 114179009
40 DRD3 NM_000796.5(DRD3): c.-388T> A single nucleotide variant Uncertain significance rs886057791 GRCh37 Chromosome 3, 113897856: 113897856

Expression for Essential Tremor

Search GEO for disease gene expression data for Essential Tremor.

Pathways for Essential Tremor

Pathways related to Essential Tremor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.97 FMR1 LINGO1 LRRK2 PRKN SLC1A2 SNCA
2 10.95 HTRA2 LRRK2 PRKN SLC6A3 SNCA
3 10.84 PRKN SLC6A3 SNCA

GO Terms for Essential Tremor

Cellular components related to Essential Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth cone GO:0030426 9.63 FMR1 LRRK2 SNCA
2 perikaryon GO:0043204 9.58 FMR1 FUS LRRK2
3 neuron projection GO:0043005 9.55 FMR1 LRRK2 PRKN SLC6A3 TENM4
4 presynapse GO:0098793 9.54 FMR1 PRKN SLC6A3
5 mitochondrial intermembrane space GO:0005758 9.5 CHCHD2 HTRA2 SNCA
6 inclusion body GO:0016234 9.43 LRRK2 SNCA
7 postsynapse GO:0098794 9.43 FMR1 LRRK2 SNCA
8 neuronal cell body GO:0043025 9.35 FMR1 FUS LRRK2 SLC6A3 SNCA
9 axon GO:0030424 9.02 FMR1 LRRK2 SLC1A2 SLC6A3 SNCA

Biological processes related to Essential Tremor according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.92 DRD3 SLC1A2 SLC6A3 SNCA
2 cellular response to oxidative stress GO:0034599 9.77 HTRA2 LRRK2 SNCA
3 locomotory behavior GO:0007626 9.76 DRD3 PRKN SLC6A3
4 negative regulation of protein phosphorylation GO:0001933 9.73 LRRK2 PRKN SNCA
5 mitochondrion organization GO:0007005 9.73 CHCHD2 HTRA2 LRRK2 PRKN
6 neuron development GO:0048666 9.72 FMR1 HTRA2 TENM4
7 adult locomotory behavior GO:0008344 9.71 HTRA2 PRKN SNCA
8 regulation of multicellular organism growth GO:0040014 9.65 DRD3 HTRA2
9 protein homotrimerization GO:0070207 9.65 HTRA2 SLC1A2
10 response to cocaine GO:0042220 9.65 DRD3 SLC6A3 SNCA
11 regulation of reactive oxygen species metabolic process GO:2000377 9.64 PRKN SNCA
12 behavioral response to cocaine GO:0048148 9.64 DRD3 SNCA
13 regulation of neuron death GO:1901214 9.63 LRRK2 SNCA
14 positive regulation of proteasomal protein catabolic process GO:1901800 9.63 FMR1 PRKN
15 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.62 LRRK2 PRKN
16 cellular protein catabolic process GO:0044257 9.61 HTRA2 PRKN
17 cellular response to dopamine GO:1903351 9.61 LRRK2 PRKN
18 prepulse inhibition GO:0060134 9.59 DRD3 SLC6A3
19 regulation of dopamine metabolic process GO:0042053 9.58 PRKN SLC6A3
20 regulation of dopamine secretion GO:0014059 9.58 DRD3 PRKN SNCA
21 dopamine biosynthetic process GO:0042416 9.57 SLC6A3 SNCA
22 regulation of neurotransmitter secretion GO:0046928 9.54 FMR1 PRKN SNCA
23 cellular response to manganese ion GO:0071287 9.52 LRRK2 PRKN
24 protein localization to mitochondrion GO:0070585 9.51 LRRK2 PRKN
25 synaptic transmission, dopaminergic GO:0001963 9.5 DRD3 PRKN SNCA
26 positive regulation of dopamine receptor signaling pathway GO:0060161 9.49 DRD3 LRRK2
27 regulation of synaptic vesicle transport GO:1902803 9.46 LRRK2 PRKN
28 negative regulation of neuron death GO:1901215 9.46 HTRA2 LRRK2 PRKN SNCA
29 dopamine metabolic process GO:0042417 9.43 DRD3 PRKN SNCA
30 regulation of locomotion GO:0040012 9.13 DRD3 LRRK2 SNCA
31 dopamine uptake involved in synaptic transmission GO:0051583 8.8 PRKN SLC6A3 SNCA

Molecular functions related to Essential Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 FMR1 FUS HTRA2 LRRK2 PRKN SNCA
2 dynein complex binding GO:0070840 9.26 FMR1 SNCA
3 phospholipase binding GO:0043274 8.96 PRKN SNCA
4 dopamine binding GO:0035240 8.62 DRD3 SLC6A3

Sources for Essential Tremor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....